Resolvin D1 and D2 inhibit transient receptor potential vanilloid 1 and ankyrin 1 ion channel activation on sensory neurons via lipid raft modification by Payrits, Maja et al.
 International Journal of 
Molecular Sciences
Article
Resolvin D1 and D2 Inhibit Transient Receptor
Potential Vanilloid 1 and Ankyrin 1 Ion Channel
Activation on Sensory Neurons via Lipid
Raft Modification
Maja Payrits 1,2, Ádám Horváth 1,2,*, Tünde Biró-Süto˝ 1,2, János Erostyák 2,3, Géza Makkai 2,3,
Éva Sághy 1,2,4, Krisztina Pohóczky 1,2,5 , Angéla Kecskés 1,2, Miklós Kecskés 2,6,
János Szolcsányi 1,†, Zsuzsanna Helyes 1,2 and Éva Szo˝ke 1,2
1 Department of Pharmacology and Pharmacotherapy, Medical School, University of Pécs, Szigeti str. 12,
H-7624 Pécs, Hungary; payrits.maja@gmail.com (M.P.); tunde.suto@aok.pte.hu (T.B.-S.);
saghy.eva@med.semmelweis-univ.hu (É.S.); pohoczkykriszti@gmail.com (K.P.);
angela.kecskes@aok.pte.hu (A.K.); janos.szolcsanyi@aok.pte.hu (J.S.); zsuzsanna.helyes@aok.pte.hu (Z.H.);
eva.szoke@aok.pte.hu (É.S.)
2 János Szentágothai Research Centre and Centre for Neuroscience, University of Pécs, Ifjúság str. 20,
H-7624 Pécs, Hungary; erostyak@fizika.ttk.pte.hu (J.E.); gezamakkai@gmail.com (G.M.);
kecskes.miklos@pte.hu (M.K.)
3 Department of Experimental Physics, Faculty of Sciences, University of Pécs, Ifjúság str. 6,
H-7624 Pécs, Hungary
4 Department of Pharmacology and Pharmacotherapy, Semmelweis University, Nagyvárad sq. 4,
H-1089 Budapest, Hungary
5 Department of Pharmacology, Faculty of Pharmacy, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary
6 Institute of Physiology, Medical School, University of Pécs, Szigeti str. 12, H-7624 Pécs, Hungary
* Correspondence: horvatadam7@gmail.com
† Professor János Szolcsányi passed away during the course of this study. This paper is dedicated to
his memory.
Received: 29 April 2020; Accepted: 13 July 2020; Published: 16 July 2020


Abstract: Transient Receptor Potential Vanilloid 1 and Ankyrin 1 (TRPV1, TRPA1) cation channels are
expressed in nociceptive primary sensory neurons and regulate nociceptor and inflammatory functions.
Resolvins are endogenous lipid mediators. Resolvin D1 (RvD1) is described as a selective inhibitor of
TRPA1-related postoperative and inflammatory pain in mice acting on the G protein-coupled receptor
DRV1/GPR32. Resolvin D2 (RvD2) is a very potent TRPV1 and TRPA1 inhibitor in DRG neurons,
and decreases inflammatory pain in mice acting on the GPR18 receptor, via TRPV1/TRPA1-independent
mechanisms. We provided evidence that resolvins inhibited neuropeptide release from the stimulated
sensory nerve terminals by TRPV1 and TRPA1 activators capsaicin (CAPS) and allyl-isothiocyanate
(AITC), respectively. We showed that RvD1 and RvD2 in nanomolar concentrations significantly
decreased TRPV1 and TRPA1 activation on sensory neurons by fluorescent calcium imaging and
inhibited the CAPS- and AITC-evoked 45Ca-uptake on TRPV1- and TRPA1-expressing CHO cells.
Since CHO cells are unlikely to express resolvin receptors, resolvins are suggested to inhibit channel
opening through surrounding lipid raft disruption. Here, we proved the ability of resolvins to
alter the membrane polarity related to cholesterol composition by fluorescence spectroscopy. It is
concluded that targeting lipid raft integrity can open novel peripheral analgesic opportunities by
decreasing the activation of nociceptors.
Keywords: Resolvin D1; Resolvin D2; lipid rafts; transient receptor potential channel; sensory neuron;
nerve terminal
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1. Introduction
The Transient Receptor Potential (TRP) Vanilloid 1 (TRPV1) and Ankyrin 1 (TRPA1) cation
channels are co-localized on capsaicin (CAPS)-sensitive polymodal nociceptors, and mediate pain and
neurogenic inflammation [1–4]. TRPV1 is gated by chemical irritants, such as CAPS, resiniferatoxin,
several endogenous arachidonic- or other fatty-acid metabolites, protons (pH < 6.0) and noxious
heat (>43 ◦C) [5–10]. TRPA1 is gated by a variety of exogenous (such as allyl-isothiocyanate—AITC)
and endogenous ligands (like primary amine metabolites, methylglyoxal [11–13]), cold (<17 ◦C),
and mechanical stimuli [14–16]. Pro-inflammatory neuropeptides, such as calcitonin gene-related
peptide (CGRP) and substance P are released from the activated TRPV1 and TRPA1-expressing
sensory nerves and induce neurogenic inflammation (vasodilatation, plasma protein extravasation,
and inflammatory cell stimulation) in the innervated area [17–19]. Neurogenic inflammation is an
important pathophysiological component of diseases like asthma, rheumatoid arthritis, psoriasis,
and inflammatory bowel diseases, and cannot be inhibited by any currently available drugs [20–22].
Furthermore, chronic neuropathic pain, in which the CAPS-sensitive nerves play an important role,
is also an unmet medical need. The refore, inhibiting function of TRPV1 and TRPA1-expressing
nociceptors is the focus of novel pharmacological approaches. Great effort has been dedicated
to developing small-molecule TRPV1 and TRPA1 antagonists [2,3,23–28], but disrupting lipid rafts
surrounding these TRP channels could also be a promising alternative way to inhibit receptor activation.
Lipid rafts are microdomains rich in cholesterol, sphingomyelins (SM), and gangliosides [29].
Cholesterol depletion by methyl β-cyclodextrin incubation resulted in impaired CAPS-evoked currents
in dorsal root ganglion (DRG) neurons [30]. We proved that pharmacological depletion of SMs,
cholesterol or gangliosides diminished TRPV1 and TRPA1 channel activation both on transfected cells
and native sensory neurons [31,32]. A very recent study showed that lipid raft destabilization by
methyl β-cyclodextrin also inhibits the responses of mouse TRPA1 to bacterial lipopolysaccharides
and cold [33]. TRPA1 was described as being located in cholesterol-rich domains. The authors
identified by in silico investigation cholesterol recognition amino acid consensus motifs in the TM2
and TM4 segments, which had a role in the inhibition of chemical activation of mouse TRPA1 by
cholesterol depletors [34]. Cholesterol might influence TRP channel function by direct interaction with
ion channels [34–36]. Sphingomyelinase hydrolyzes SM to phosphocholine and ceramide [37,38]. It did
not only act on the sensory neuronal cell bodies, but also on the nerve terminals diminishing TRPV1 and
TRPA1 activation-induced CGRP release, as a good indicator of channel inhibition [31]. The described
changes of the plasma membrane composition related to lipid raft disruption could be investigated in
a reliable manner by fluorescence spectroscopy, as have been reported earlier [31,32,39,40].
Identifying the endogenous inhibitors of TRPV1 and TRPA1 channels could open novel
perspectives to understand their pharmacological opportunities. Resolvins are lipid mediators
with pro-resolving and anti-inflammatory functions [41,42]. Resolvin D1 (RvD1) is derived from
docosahexaenoic acid (Figure 1) [42] and is a potent inhibitor of inflammatory and postoperative pain,
but its molecular mechanism of action is unclear [43–45]. RvD1 was described as a selective inhibitor
of TRPA1 in DRG neurons [43]. Resolvin D2 (RvD2)—which is also a docosahexaenoic acid derivate
(Figure 1)—is a regulator of leukocyte functions and controls sepsis [46]. RvD2 has been reported as a
very potent TRPV1 and TRPA1 inhibitor in DRG neurons, which inhibited cation influx in nanomolar
concentration (IC50 0.1 nM for TRPV1 and IC50 2.1 nM for TRPA1) [47]. Peripheral and central
administration of its low dose (0.01–10 ng) decreased acute, subacute, and persistent inflammatory
pain in mouse models via TRPV1/TRPA1-independent mechanisms. This effect was suggested to be
mediated by its specific G protein-coupled receptor (GPR) [47], which was later identified by direct
binding of 3H-labeled RvD2. It is called GPR18 when described on human leukocytes, including
polymorphonuclear neutrophil cells, monocytes, and macrophages [48]. DRV1/GPR32 is the receptor
for RvD1 identified in human leukocytes [49,50].
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were observed in the case of AITC, resulting in 0.66 ± 0.05 and 0.29 ± 0.02 R values, respectively 
(Figure 2E–H). Original recordings of CAPS- and AITC-induced Ca2+-influx in TG neurons are 
presented in Figure 3. 
The overnight pertussis toxin (PTX) treatment did not prevent the inhibitory effect of the higher 
doses of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation (Figure 4A,B). Neither RvD1 nor 
RvD2 affected the 50 mM KCl-evoked voltage-gated Ca2+ channel activation (Figure 4C). 
Figure 1. Structure of RvD1 and RvD2.
The present study investigated the effects of RvD1 and RvD2 on TRPV1 and TRPA1 receptor
activation on trigeminal sensory neurons and peripheral sensory nerve endings and the involvement
of lipid raft modification around these nocisensor ion channels in their mechanisms of action.
2. Results
2.1. RvD1 and RvD2 Inhibit TRPA1 and TRPV1 Receptor Activation-Mediated Ca2+-Influx in Cultured
Trigeminal Ganglion (TG) Neurons
Firstly, the percentage of responding neurons with Ca2+-influx to 330 nM CAPS and 200 µM
AITC was determined i control plates. In control plates, CAPS- and AITC-in uced Ca2+-influx were
detected in 57.1 ± 8% (60 out of 104, the R value was 0.99 ± 0.05) and 25.6 ± 5.6% (43 out of 170, the R
value was 0.98 ± 0.07) of the cells, respectively. RvD1 treatment in 10 nM significantly decreased not
just the proportion of cells responding to CAPS and AITC resulting in 42.1 ± 6.5% (40 out of 94) and 7
± 3.2% (8 out of 91) responsive cells, respectively, but also the R values, resulting in R = 0.73 ± 0.07 and
0.46 ± 0.06, respectively. After 2 nM RvD1 incubation, the percent of re ponsive cells to CAPS was
unaffect d (59.5 ± 7% (63 out of 106)), while it diminished the AITC-evoked responses o 14.3 ± 3.4%
(12 out of 84) (Figure 2A–D).
Significant decreases in the percent of CAPS- and AITC-s nsitive cells were observed after 2
and 10 M RvD2 incubation, resulting in 44.8 ± 5.8% (48 out of 108) and 17 ± 3.3% (18 out of 102)
in the case of CAPS and 18.1 ± 3.7% (20 out of 108) and 11 ± 4.1% (9 out of 89) responsive cells
in the case of AITC, respectively (Figure 2E–H). The related R values in the case of CAPS have
been decreased also to 0.71 ± 0.05 and 0.35 ± 0.05 after 2 and 10 nM RvD2 incubation, respectively,
and similar decreases were observed in the case of AITC, resulting in 0.66 ± 0.05 and 0.29 ± 0.02 R
values, respectively (Figure 2E–H). Original recordings of CAPS- and AITC-induced Ca2+-influx in TG
neurons are presented in Figure 3.
The overnight pertussis toxin (PTX) treatment did not prevent the inhibitory effect of the higher
doses of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation (Figure 4A,B). Neither RvD1 nor
RvD2 affected the 50 mM KCl-evoked voltage-gated Ca2+ channel activation (Figure 4C).
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Change in the fluorescence ratio (R = F340/F380) after TRPV1 receptor activation in CAPS-sensitive cells is 
presented after B: RvD1 and E: RvD2 treatment. C,G: The percentage of responsive cells to allyl-isothiocyanate 
(AITC) is presented after C: RvD1 (2 and 10 nM, n = 84–170 cells per group) and G: RvD2 (2 and 10 nM, n = 89–
170 cells per group) administration. D,H: Change in the fluorescence ratio (R = F340/F380) after TRPA1 receptor 
activation in AITC-sensitive cells is presented after D: RvD1 and H: RvD2 treatment. Ca2+-responses are 
Figure 2. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on cultured trigeminal
ganglion sensory neurons. (A,E): The percentage of responsive cells to capsaicin (CAPS) is presented
after (A): RvD1 (2 and 10 nM, n = 94–106 cells per group) and (E): RvD2 (2 and 10 nM, n = 102–108 cells
per group) administration. (B,F): Change i the fluo scence ratio (R = F340/F380) after TRPV1
receptor activation in CAPS-sensitive cells is presented after (B): RvD1 and (E): RvD2 treatment.
(C,G): The percentage of responsive cells to allyl-isothiocyanate (AITC) is presented after (C): RvD1
(2 and 10 nM, n = 84–170 cells per group) and (G): RvD2 (2 and 10 nM, n = 89–170 cells per group)
administration. (D,H): Change in the fluorescence ratio (R = F340/F380) after TRPA1 receptor activation
in AITC-sensitive cells is presented after (D): RvD1 and (H): RvD2 treatment. Ca2+-responses are
presented in % of total number of examined neurons. (* p < 0.05, ** p < 0.01, *** p < 0.001 (control vs.
treated, one-way ANOVA, Dunnett’s post hoc test).
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Figure 3. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on cultured TG sensory 
neurons. Increases in R=340/380 fluorescence in fura-2 loaded cultured TG neurons. Original 
recording from CAPS (A,C,E)- and AITC (B,D,F)-sensitive neurons on control (A,B), RvD1-treated 
(C,D) or RvD2-treated (E,F) plates. 
Figure 3. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on cultured TG sensory
neurons. Increases in R = 340/380 fluorescence in fura-2 loaded cultured TG neurons. Original recording
from CAPS (A,C,E)- and AITC (B,D,F)-sensitive neurons on control (A,B), RvD1-treated (C,D) or
RvD2-treated (E,F) plates.
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Figure 4. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on cultured TG sensory 
neurons after PTX treatment and on KCl-evoked voltage gated Ca2+ channel activation. A: The 
percentage of responsive cells to CAPS is presented after RvD1 or RvD2 (both of them 10 nM) 
administration. B: The percentage of responsive cells to AITC is presented after RvD1 or RvD2 (both 
Figure 4. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on cultured TG
sensory neurons after PTX treatment and on KCl-evoked voltage gated Ca2+ channel activation.
(A): The percentage of responsive cells to CAPS is presented after RvD1 or RvD2 (both of them 10 nM)
administration. (B): The percentage of responsive cells to AITC is presented after RvD1 or RvD2 (both
of them 10 nM) administration. (C): The percentage of responsive cells to KCl is presented after RvD1
or RvD2 (both f them 10 nM) administration. (* p < 0.05, *** p < 0.001 (c trol vs. tr ated, one-way
ANOVA, Dunnett’s post hoc test).
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2.2. RvD1 and RvD2 Decrease TRPV1 and TRPA1 Activation-Evoked CGRP Release from Peripheral
Sensory Nerves
TRPV1 activation by 100 nM CAPS induced 1.2 ± 0.19 fmol/mg CGRP release from the sensory
nerves of the rat trachea. TRPA1 activation by 100 µM AITC evoked 0.57 ± 0.1 fmol/mg CGRP outflow,
which is approximately half of the effect of CAPS. RvD1 significantly decreased the CAPS-evoked
CGRP release in 100 nM concentration to 0.8 ± 0.09 fmol/mg (Figure 5A) and the AITC-induced
peptide outflow in 50 and 100 nM concentration to 0.32 ± 0.09 fmol/mg and 0.27 ± 0.1 fmol/mg
(Figure 5B). RvD2 was able to diminish the CGRP release in a ten-fold lower concentration. It decreased
significantly the CAPS- and AITC-evoked CGRP release in 5 nM concentration to 0.89 ± 0.15 and
0.29 ± 0.11 fmol/mg, respectively, and in 10 nM concentration to 0.67 ± 0.19 and 0.22 ± 0.02 fmol/mg,
respectively (Figure 5C,D). RvD1 and RvD2 did not influence the basal, non-stimulated peptide outflow
(data not shown) and KCl-evoked CGRP release (Figure 5E).
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Figure 5. Effect of RvD1 and RvD2 on TRPV1 and TRPA1 receptor activation on peripheral nerve
terminals. (A,B): Effect of 10, 50, and 100 nM RvD1 on 100 nM CAPS-evoked (A) or 100µM AITC-evoked
(B) CGRP release. (C,D): Effect of 1, 5, and 10 nM RvD2 on 100 nM CAPS-evoked (C) or 100 µM
AITC-evoked (D) CGRP release. (E): Effect of 100 nM RvD1 and 10 nM RvD2 on 50 mM KCl-evoked
CGRP release. Each column represents the mean + SEM of values of 6–8 experiments. As this
method is a radioimmunoassay, CGRP release is represented as CGRP-like immunoreactivity (CGRP-LI)
(* p < 0.05, ** p < 0.01, *** p < 0.001 control vs. treated, one-way ANOVA, Dunnett’s post hoc test).
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2.3. RvD1 and RvD2 Inhibit the CAPS- and AITC-Evoked 45Ca-Uptake on Chinese Hamster Ovary (CHO)
Cells Expressing the Cloned TRPV1 and TRPA1 Receptor
A significant decrease in CAPS-evoked 45Ca-accumulation was observed when CAPS was
co-administered with 10 nM RvD1 on TRPV1-expressing CHO cells. The percent value of 45Ca-uptake
relative to the untreated control (100%) was 68.33± 18.14% after RvD1 treatment (Figure 6A). The highest
concentration of RvD2 was able decreased the CAPS-evoked 45Ca-uptake, and the percent value was
46 ± 14.4% relative to the untreated control (Figure 6C).
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cells in radioactive 45Ca-uptake experiments after CAPS (100 nM) and AITC (100 μM) administration. 
45Ca-accumulations are presented in % of control (non-treated). Each column represents the 
mean+SEM of values of nine experiments. (* p <0.05, ** p <0.01, *** p <0.001 (control vs. treated, one-
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Figure 6. Effect of RvD1 and RvD2 on CAPS- and AITC-evoked 45Ca-uptake on CHO cells expressing
the cloned TRPV1 and TRPA1 receptor. (A,B): Effect of RvD1 on TRPV1-expressing (A) and
TRPA1-expressing (B) CHO cells in radioactive 45Ca-uptake experiments after CAPS (100 nM) and
AITC (100 µM) administration. (C,D): Effect of RvD2 on TRPV1-expressing (C) and TRPA1-expressing
(D) CHO cells in radioactive 45Ca-uptake experiments after CAPS (100 nM) and AITC (100 µM)
administration. 45Ca-accumulations are presented in % of control (non-treated). Each column
represents the mean + SEM of values of nine experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001
(control vs. treated, one-way ANOVA, Dunnett’s post hoc test).
Both 5 and 10 nM RvD1 and RvD2 significantly diminished the AITC-induced 45Ca-uptake relative
to the control, and these values were 62.66 ± 21.2% and 48 ± 14.9% in the case of RvD1 and 57 ± 19%
and 44 ± 6.2% in the ca e of RvD2, resp ctively (Figure 6B,D).
2.4. RvD1 and RvD2 Change the Membrane Polarity on CHO Cells
To investigate the effect of RvD1 and RvD2 on lipid raft integrity, fluorescent spectroscopy
measurements with 6-dodecanoyl-N,N-dimethyl-2-naphthylamine (Laurdan)—a membrane polarity
selective probe—were performed on CHO cells.
There is no spectral shift, broadening or any change in the shape of the spectra, but serious
intensity change can be seen, which means that the micro-environment of Laurdan is changed by both
RvD1 and RvD2 (Figure 7A,B).
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Excitation wavelength: 440 nM, emission wavelength: 355 nM. Solid (black) or dashed and solid (red)
curves represent the RvD1 or RvD2 and non-treated control samples, respectively.
Excitation–emission matrices also show that the RvD1- and RvD2-treated samples (cultured CHO
cells) (Figure 8A,B) have higher fluorescence intensity than the non-treated control sample (Figure 8C)
on the entire spectral region of fluorescence of Laurdan. The anisotropy values are practically the
same on the whole spectral range in the case of RvD1-, RvD2-treated, and non-treated control samples
(Figure 8D).
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3. Discussion
This is the first paper providing evidence that resolvins inhibit the activation of TRPV1 and
TRPA1 ion channels on sensory nerve terminals besides the cell bodies via modifying the membrane
composition and lipid rafts. Our results on TG neurons confirm that RvD2 is a potent inhibitor of the
TRPV1 and TRPA1 receptors in nanomolar concentrations. In contrast to the earlier studies conducted
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on DRG neurons [47], we showed that RvD1 treatment in 10 nM concentration significantly decreased
both the magnitude of Ca2+-influx in TG neurons and the proportion of cells responding to TRPV1
activation in addition to TRPA1 stimulation. Similarly to the literature data [47], RvD2 had more
pronounced inhibitory action on both TRPV1 and TRPA1 channels. PTX pretreatment did not affect the
inhibitory effect of the 10 nM doses of RvD1 and RvD2 on TRPV1 and TRPA1 ion channel activity in
cultured TG neurons. Previous studies described that pretreatment of DRG cultures with PTX blocked
inhibitory effects of lower concentration (1 nM) of RvE1 on capsaicin-induced TRPV1 activation [51].
Another study described that PTX treatment also blocked the effect of nanomolar doses of RvD1 and
RvD2 on TRPV1 and TRPA1 channel activation [47]. Our results with higher doses of resolvins suggests
another G-protein-independent way of inhibition. KCl-evoked voltage-gated Ca2+ channel activation
remained unaltered after RvD1 or RvD2 treatment. The trachea is a good model system to examine
the activation of sensory nerve terminals because the nerves are close to the surface and they can be
easily stimulated [52,53]. RvD2 concentrations (5 and 10 nM) to reduce TRPV1 and TRPA1 activation
on the sensory nerve terminals shown by the decreased CGRP release were similar to that needed for
the inhibitory action on the isolated cell bodies. However, 10-fold higher concentrations of RvD1 had
to be used to exert similar inhibitory actions to RvD2 on the nerve endings, which might be explained
by its weaker penetration abilities into deeper tissue layers. Neither RvD1 nor RvD2 decreased the
50 mM KCl-induced CGRP release.
RvD1 was originally characterized as a selective TRPA1 inhibitor in DRG neurons and human
embryonic kidney cells in nanomolar concentration by patch clamp and calcium imaging studies [43,47].
However, RvD1 inhibited fluorescent Ca2+-influx into TG sensory neurons in our experimental system
in response to both TRPV1 and TRPA1 activations, although higher concentration (10 nM) was
needed for TRPV1 inhibition. In contrast to RvD1, RvD2 was described as a potent inhibitor of both
TRPV1 and TRPA1 in DRG cells, with a 20-fold higher potency for TRPV1 (IC50: 0.1 and 2.1 nM
for TRPV1 and TRPA1, respectively). Peripheral and central administration of RvD2 in very low
doses (0.01–10 ng) attenuated Complete Freund’s adjuvant-induced inflammatory pain-related spinal
long-term potentiation in mice in a TRPV1/TRPA1-independent manner [47]. It has been suggested
that pro-resolving mediators such as RvD1 exert activity via specific GPRs, similarly to lipoxin A4 and
Resolvin E1 [42]. The RvD1 receptor named DRV1/GPR32 was identified via library screening and
with 3H-labeled ligand binding [49]. RvD1 was reported as an endogenous inhibitor for the TRPA1,
TRPV3, and TRPV4 channels by Ca2+ imaging experiments on transfected HEK293T cells and whole
cell patch-clamp and Ca2+ imaging experiments on mouse DRG sensory neurons. RvD1 suppressed
the three TRP channels-mediated nociceptive behaviors in mice [43]. The naturally occurring
pro-resolving lipid 17R-RvD1 is a specific inhibitor of TRPV3. The results of Ca2+ imaging and whole
cell electrophysiology experiments on receptor-expressing HEK cells, sensory neurons, keratinocytes,
and behavioral studies suggest that 17R-RvD1 has an acute analgesic effect on TRPV3 ion channels [54].
Intrathecal RvD1 administration prevented postoperative hyperalgesia and mechanical allodynia in a
skin–muscle retraction rat model [45]. Intrathecal RvD1 treatment prevented mechanical allodynia in a
chronic pancreatitis model [55]. Feng and co-workers suggest that RvD1 attenuated the phosphorylation
of nMDA receptor subunits and down-regulated the expression of inflammatory cytokines in the spinal
dorsal horn [55]. Pretreatment with the selective Gαi-coupled GPR inhibitor pertussis toxin as well as
the G-protein blocker guanosine-5′-(β-thio)-diphosphate sodium salt prevented the RvD2-induced
inhibition of TRPV1- and TRPA1-mediated responses on DRG sensory neurons, providing evidence
for GPR-mediated actions [47]. Later, GPR18 was identified as the receptor for RvD2 by 3H-labeled
ligand binding and receptor knockout mice. GPR18 expression was describe on human leukocytes,
including polymorphonuclear neutrophil cells, monocytes, and macrophages [48].
On TRPV1-expressing CHO cells, RvD1 and RvD2 induced significant decrease in CAPS-evoked
45Ca-accumulation only at 10 nM concentrations. However, both 5 and 10 nM RvD1 and
RvD2 significantly and concentration dependently decreased the AITC-induced 45Ca-uptake on
TRPA1-expressing CHO cells. Since these cells are unlikely to express the resolvin receptors, RvD1
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and RvD2 are suggested to inhibit TRP channel activation through surrounding lipid raft disruption.
The results that PTX pretreatment did not affect the inhibitory effect of the higher 10 nM doses of
RvD1 and RvD2 on TRPV1 and TRPA1 ion channel activation in cultured TG neurons also suggest
G-protein-independent way of inhibition. KCl-induced Ca2+-influx in TG cells and CGRP release
from sensory nerve endings remained unaltered after RvD1 or RvD2 treatment. Our previous results
confirmed that lipid raft disruption did not alter KCl-evoked voltage-gated Ca2+ channel activation [31].
Here, we provide the first direct evidence by fluorescence spectroscopy for the ability of RvD1 and
RvD2 to induce transition from liquid-ordered to liquid-disordered phase in the plasma membrane,
indicating cholesterol depletion [30–32] and leading to lipid rafts disintegration. High intensity change,
but no anisotropy, was observed after both resolvin treatments, indicating less non-radiative processes
of Laurdan, less interactions with its micro-environment, and rotational motion restricted to the
non-treated control level within the membrane [31,32].
We showed here a dual inhibitory effect of RvD1 and RvD2 on TRPV1 and TRPA1 ion channels
via surrounding lipid raft decomposition in the membrane. The se results suggest that targeting lipid
raft integrity can open novel peripheral analgesic opportunities by decreasing the activation potentials
of nociceptors.
4. Materials and Methods
4.1. Primary Cultures of TG Neurons
Cells of TG of 1–4 days old Wistar rat pups (6 pups/experiment) were cultured. The ganglia
were cut and placed into ice cold phosphate-buffered saline (PBS), incubated for 35 min at 37 ◦C
in PBS containing collagenase (Type XI, 1 mg/mL), and then, in PBS with deoxyribonuclease I
(1000 units/mL) for 8 min. The ganglia were then dissociated by trituration. Cell cultures were plated
on poly-D-lysin-coated glass coverslips and grown in a nutrient-supplemented medium that contained
180 mL Dulbecco’s-Modified Eagle Medium (DMEM), 20 mL horse serum, 20 mL bovine albumin, 2 mL
insulin-transferrin-selenium-S, 3.2 mL putrescin dihydrochloride (100 µg/mL), 20 µL triiodo-thyronine
(0.2 mg/mL), 1.24 mL progesterone (0.5 mg/mL), 100 µL penicillin, and 100 µL streptomycin. Cultures
were maintained at 37 ◦C in a humidified atmosphere with 5% CO2, and nerve growth factor (NGF,
200 ng/mL) was added every second day, as described earlier [56].
4.2. Ratiometric Technique of Intracellular Free Calcium Concentration ([Ca2+]i) Measurement with the
Fluorescent Indicator Fura-2-Acetoxymethyl Ester (Fura-2-AM)
One to three-days-old cell cultures were stained for 30 min at 37 ◦C with 1 µM of fluorescent Ca2+
indicator dye—fura-2-AM (Molecular Probes)—then, washed in extracellular solution (ECS). ECS was
gravity fed to the cells using a triple outlet tube and test solutions arrived at the outlet via separate
tubes. We could control the rapid changing of solutions by a fast step perfusion system (VC-77SP,
Warner Instrument Corporation, Harvard Apparatus GmbH, Freiburg, Germany). Calcium transients
of TG neurons to CAPS (stimulation was 10 s) and AITC (stimulation was 15 s) were examined with
microfluorimetry, as described elsewhere [56]. Fluorescence images were taken with an Olympus
LUMPLAN FI/x20 0.5 W water immersion objective and a digital camera (CCD, SensiCam PCO,
Kelheim, Germany), connected to a computer. Cells were illuminated alternately with 340 and 380 nM
light generated by a monochromator (Polychrome II., Till Photonics, Kaufbeuren, Germany) under the
control of Axon Imaging Workbench 2.1 (AIW, Axon Instruments, CA). We measured the emitted light
>510 nM. The R = F340F380 was monitored (rate 1 Hz) continuously for up to 2 min, while a few sample
images were also recorded. The R values were generated by AIW 2.1 software, then, processed by
the Origin software version 8.0 (Originlab Corp., Northampton, MA, USA). Baseline was adjusted to
R = 0, and the peak magnitude of ratiometric responses was calculated.
Neurons were incubated with 1 µg/mL PTX overnight, 2 and 10 nM RvD1 and RvD2 for
60 min, respectively, at 37 ◦C in a humidified atmosphere with 5% CO2, or were untreated controls.
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To investigate the voltage-gated ion channel alteration, 50 mM KCl was applied after RvD1 and
RvD2 incubation.
4.3. Measurement of TRPV1/TRPA1 Activation-Induced CGRP Release from Sensory Nerve Endings of the
Isolated Rat Trachea
This method has been described in detail elsewhere [52,53]. In brief, rats (age of 30–40 weeks;
in total, 196 animals) were exsanguinated in deep anesthesia (sodium thiobarbital 50 mg/kg
intraperitoneal), then, tracheae were removed, cleaned of fat and adhering connective tissues, and placed
into an organ bath to achieve sufficient amounts of peptide release and perfused (1 mL/min) with pH
7.2 controlled oxygenated Krebs solution for 60 min (equilibration period) at 37 ◦C. The n, they were
incubated in the presence of RvD1 (10, 50, and 100 nM) or RvD2 (1, 5, and 10 nM) for 60 min or left
untreated for control. The trachea is an excellent model to investigate the activation of peripheral
nerve terminals. The se nerve endings are close to the surface and they can be easily stimulated by
different agonists. After discontinuation of the flow, the solution was changed three times for 8 min to
produce pre-stimulated, stimulated and post-stimulated fractions. Chemical activation was performed
in the second 8 min period, with the selective TRPV1 agonist CAPS (100 nM) or the TRPA1 agonist
AITC (100 µM) or KCl (50 mM) to elicit CGRP release. CGRP concentrations were determined from
200 µL samples of organ fluid of the preparations by means of radioimmunoassay methods developed
in our laboratories as described [52,53]. CGRP concentrations were measured also from the media of
non-stimulated samples in the presence of resolvins to determine their effect on the baseline peptide
release. The trachea samples were weighed and CGRP release was calculated as fmol/mg wet tissue.
The absolute peptide outflow in response to the chemical stimulations was calculated by adding CGRP
release measured in the stimulated and post-stimulated fractions after subtracting the basal release
measured in the pre-stimulated 8 min fraction. In each group, 6 experiments were performed per
group (12 tracheae per group; 2 tracheae in each organ bath chamber).
4.4. Radioactive 45Ca-Uptake Experiments in CHO Cells Expressing Cloned TRPV1 or TRPA1 Receptors
CHO cells stably expressing the human TRPV1 or rat TRPA1 receptor were plated into the
medium onto Microwell minitrays (Sigma Inc., Marlborough, MA, USA) in 15 µL cell culture, similarly
as described earlier for HT1080 cells [57]. The following day, the cells were washed 5 times with
calcium-free Hank’s solution (pH 7.4), then, incubated in 15 µL of the same buffer containing the
desired amount of RvD1 and RvD2 (1, 5, and 10 nM) on 37 ◦C for 60 min. After washing with Hank’s
solution, the cells were incubated in 10 µL of the same buffer containing 100 nM CAPS or 100 µM AITC
and 200 µCi/mL 45Ca isotope (1.3 Ci/mM, Amersham) for 2 min at room temperature. After washing
5 times with ECS, the residual buffer was evaporated. The n, the retained isotope was collected in
15 µL 0.1% sodium dodecyl sulphate and the radioactivity was measured in 2 mL scintillation liquid in
a Packard Tri-Carb 2800 TR scintillation counter.
4.5. Fluorescence Spectroscopy to Determine Membrane Polarity Related to Lipid Raft Integrity
CHO cells were incubated with Laurdan in 40 µM final concentration for 40 min at 37 ◦C in a
humidified atmosphere with 5% CO2. Laurdan is a membrane probe that is sensitive to the polarity
of the membrane [40,58]. RvD1 and RvD2 in 100 nM were diluted with ECS and added to the cell
wells for 45 min at 37 ◦C before Laurdan administration, respectively. Cells were then washed 3
times with PBS and scraped from the plates into 1 mL PBS. Fluorescence excitation and emission
spectra, excitation–emission matrices, and anisotropy spectra were measured by a HORIBA Jobin-Yvon
Nanolog FL3-2iHR spectrofluorometer equipped with a 450 W xenon lamp. Samples were measured
in a 4 mM path length quartz cuvette (Hellma 104F-QS) and kept at a constant 20 ◦C using a Thermo
Scientific circulating bath AC200-A25. Excitation–emission matrices consisting of a series of emission
spectra recorded at different excitation wavelengths were measured to determine spectral changes.
An excitation–emission matrix has one axis for the emission wavelengths, while the other includes the
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excitation wavelengths. At the intersection points, fluorescence intensity can be read as the value of
the third axis. Steady-state emission anisotropy was measured in “L-format” arrangements to study
the molecular mobility. Excitation was vertically polarized, while anisotropy was calculated from
consecutively measured vertical and horizontally polarized emission intensities. Anisotropy <r> is
defined as
< r >=
IVV−G ∗ IVH
IVV+2 ∗G ∗ IVH
where G is the spectrofluorometer’s sensitivity factor given by:
G =
IHV
IHH
where IHV and IHH are measured using horizontally polarized excitation and vertically and horizontally
polarized emission, respectively. The G value was automatically recalculated at each wavelength point
of the anisotropy measurements.
4.6. Drugs and Chemicals
CAPS and AITC (Sigma, St. Louis, MO, USA) were dissolved in dimethyl sulfoxide (DMSO) to
obtain a 10 mM stock solution. Further dilutions were made with ECS or Krebs solution to reach
final concentrations of 330 and 100 nM in the case of CAPS and 200 or 100 µM in the case of AITC,
respectively. RvD1 an RvD2 were purchased from Cayman Chemical in an ethanolic solution. Laurdan
was purchased from Sigma and dissolved in (DMSO) to obtain a 10 mM stock solution. PTX was
purchased from Sigma and dissolved in ECS. DMEM, horse serum, fetal bovine albumin, and newborn
calf serum were purchased from Gibco (Grand Island, NY, USA). Collagenase, deoxyribonuclease I,
poly-D-lysine, and NGF were purchased from Sigma.
4.7. Statistical Analysis
The Kolmogorov–Smirnov normality test showed normal distribution for all data sets;
we performed the analysis of variance (ANOVA) for statistical analysis. Data reported in this
paper are the means ± SEM of six to eight independent experiments in the case of Ca2+-influx
measurement in cultured TG neurons and measurement of CGRP release, and nine independent
experiments in the case of 45Ca-uptake experiments in CHO cells. In the CGRP release measurements
in each group six experiments were performed per group (12 tracheae per group; 2 tracheae in each
organ bath chamber). Fluorescence spectroscopy measurements were performed with four samples
per group. Statistical analysis was performed by one-way ANOVA with Dunnett’s post hoc test; in all
cases p < 0.05 was considered statistically significant.
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Abbreviations
[Ca2+]i intracellular free calcium concentration
AITC allyl isothiocyanate
CAPS capsaicin
CHO Chinese hamster ovary
CGRP calcitonin gene-related peptide
DMEM Dulbecco’s Modified Eagle Medium
DMSO dimethyl sulfoxide
DRG dorsal root ganglion
ECS extracellular solution
fura-2-AM fura-2-acetoxymethyl ester
GPR G protein-coupled receptor
Laurdan 6-dodecanoyl-N,N-dimethyl-naphthylamine
NGF nerve growth factor
PBS phosphate-buffered saline
PTX Pertussis toxin
RvD1 Resolvin D1
RvD2 Resolvin D2
SM sphingomyelin
TG trigeminal ganglion
TRP Transient Receptor Potential
TRPA1 Transient Receptor Potential Ankyrin 1
TRPV1 Transient Receptor Potential Vanilloid 1
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